----- Original Message ----- From: "m .c. ptrwn" <[EMAIL PROTECTED]> To: "teknologia" <[email protected]> Sent: Monday, February 06, 2006 11:45 PM Subject: [teknologia] Re: Obat Sanaflu mengandung PPA (PhenylPropanolAmine) yang berbahaya
> FDA ada mailing-listnya untuk untuk memberitahu keputusan tentang obat > atau medical device yang harus di recall. > > Waduh mereka aktif sekali dan sering bikin shock industri Pharma/biotek > , mungkin dalam satu bulan ada beberapa obat yg direcall. Kalaupun > tidak direcall sering kali dengar lawsuit melawan > pharma/biotek/healthcare company. > > > Carlos > PPA ini sekarang sudah di larang, bahkan untuk anak-anak coba dech iseng-iseng ke sini www.mims-online.com lucunya..... Ann Epidemiol. 2006 Jan;16(1):49-52. Phenylpropanolamine and Hemorrhagic Stroke in the Hemorrhagic Stroke Project: A Reappraisal in the Context of Science, the Food and Drug Administration, and the Law. Stier BG, Hennekens CH. Mr. Stier is from the Southwestern University School of Law, Los Angeles, CA and Dr. Hennekens is from the Departments of Medicine, Epidemiology, and Public Health, University of Miami School of Medicine, Miami, FL, and Department of Biomedical Science, Center of Excellence, Florida Atlantic University, Boca Raton, FL. The report of the Hemorrhagic Stroke Project (HSP), a case-control study of phenylpropanolamine (PPA) was the primary reason that the US Food and Drug Administration (FDA) requested that PPA-containing products voluntarily be withdrawn from the market. In subsequent litigation, scientific information emerged that was not available during the deliberations of the FDA and its advisory committee. Our reappraisal leads us to conclude that chance, bias, and confounding are plausible alternative explanations for the observed findings. Thus, we believe that it is not possible to conclude that there is any valid statistical association between PPA and hemorrhagic stroke, let alone make any judgment of causality. Our reappraisal suggests the FDA's regulatory request may have been premature. akan tetapi : Kalau kita buka EBMnya di cochrane perihal efedrin/pseudiefedrin, tertera bahwa efektivfitasnya hanya sepuluh jam pertama dan tidak terbukti efektivitasnya pada pemberian yang berulang dan tidak terbukti efektivitasnya pada anak DECONGESTANTS: short-term relief of nasal obstruction for adults, but may not work in children. Are often used, but evidence that they work is scanty. Trials show that single doses are moderately effective. Insufficient evidence to show whether: - repeated doses are effective, or whether - single or repeated doses work in children age < 12. http://www.cochrane.org/reviews/english/ab001953.html Kalau aku sih lebih baik banyakin air putih hangat aja yah. wongcilik
